The clinical course of untreated Gaucher disease in 22 patients over 10 years: Hematological and skeletal manifestations

Blood Cells, Molecules, and Diseases

Volumn 43, Issue 3, 2009, Pages 289-293

  Piran, Siavash ^a   Roberts, Andrew ^a   Patterson, Mary Anne ^a   Amato, Dominick ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Bone disease; Disease progression; Enzyme replacement therapy; Type 1 Gaucher disease

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE; FERRITIN; HEMOGLOBIN; VITAMIN D;

ADULT; AGED; ARTICLE; AVASCULAR NECROSIS; BONE DISEASE; BONE MALFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GAUCHER DISEASE; HEMATOLOGIC DISEASE; HEMOGLOBIN DETERMINATION; HEPATOMEGALY; HUMAN; LIVER WEIGHT; MALE; OSTEOPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPLEEN SIZE; SPLENOMEGALY; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DISEASES; FEMALE; FOLLOW-UP STUDIES; GAUCHER DISEASE; GENOTYPE; HEMOGLOBINS; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LIVER; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PLATELET COUNT; RETROSPECTIVE STUDIES; SPLEEN;

EID: 71749087023     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2009.08.002     Document Type: Article

References (21)

1. Grabowski G.A., Barton N.W., Pastores G., et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 122 (1995) 33-39
2. Heukamp L.C., Schröder D.W., Plassmann D., et al. Marked clinical and histologic improvement in a patient with type-1 Gaucher's disease following long-term glucocerebroside substitution. A case report and review of current diagnosis and management. Pathol. Res. Pract. 199 (2003) 159-163
3. Hollak C.E., Aerts J.M., Goudsmit R., et al. Individualised low-dose alglucerase therapy for type 1 Gaucher disease. Lancet 345 (1995) 1474-1478
4. Grabowski G.A., Leslie N., and Wenstrup R. Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev. 12 (1998) 115-133
5. Wenstrup R.J., Kacena K.A., Kaplan P., et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J. Bone Miner. Res. 22 (2007) 119-126
6. Poll L.W., Koch J.A., vom Dahl S., et al. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol. 30 (2001) 496-503
7. de Fost M., van Noesel C.J., Aerts J.M., et al. Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica 93 (2008) 1119-1120
8. Mistry P.K., Sadan S., Yang R., et al. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am. J. Hematol. 82 (2007) 697-701
9. Grabowski G.A. Recent clinical progress in Gaucher disease. Curr. Opin. Pediatr. 17 (2005) 519-524
10. Pastores G.M., Patel M.J., and Firooznia H. Bone and joint complications related to Gaucher disease. Curr. Rheumatol. Rep. 2 (2000) 175-180
11. Bembi B., Ciana G., Mengel E., et al. Bone complications in children with Gaucher disease. Br. J. Radiol. 75 (2002) A37-44
12. Drelichman G., Ponce E., Basack N., et al. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. J. Pediatr. 151 (2007) 197-201
13. Charrow J., Andersson H.C., Kaplan P., et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J. Pediatr. 144 (2004) 112-120
14. Zimran A., Kay A., Gelbart T., et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 71 (1992) 337-353
15. Beutler E., Demina A., Laubscher K., et al. The clinical course of treated and untreated Gaucher disease. A study of 45 patients. Blood Cells Mol. Dis. 21 (1995) 86-108
16. Ida H., Rennert O.M., Ito T., et al. Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. Blood Cells Mol. Dis. 24 (1998) 73-81
17. Niederau C., Brikhahn A., Ehlen C., and Haussinger D. Facts and fiction of modern diagnosis of type 1 Gaucher disease: the German experience. Gaucher Clin. Perspect. 4 (1996) 5-13
18. Maaswinkel-Mooij P., Hollak C., van Eysden-Plaisier M., et al. The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J. Inherit. Metab. Dis. 23 (2000) 77-82
19. Dweck A., Abrahamov A., Hadas-Halpern I., et al. Type I Gaucher disease in children with and without enzyme therapy. Pediatr. Hematol. Oncol. 19 (2002) 389-397
20. Rodrigue S.W., Rosenthal D.I., Barton N.W., et al. Risk factors for osteonecrosis in patients with type 1 Gaucher's disease. Clin. Orthop. Relat. Res. 362 (1999) 201-207
21. Cormand B., Grinberg D., Gort L., et al. Two new mild homozygous mutations in Gaucher disease patients: clinical signs and biochemical analyses. Am. J. Med. Genet. 70 (1997) 437-443